Volume and action support your thesis. The real question is when will it end and how much info will be released when that happens. Definitely games being played. Trying to play with them not against them.
The company has enough cash now to run its operations for a few months at least but needs more cash reserve for forthcoming more expensive Phase II-III efficacy trials after the safety trials are satisfactorily over. Therefore, Lincoln Park may continue doing this little by little for several months. Of course, Lincoln Park is in to make money and not loose money. Thus, with the money it's providing to the company, the company may facilitate Lincoln Park's investment at the best price possible while giving it some clues as to where the trial results are headed.
Unless RS is done and the company enters into Phase II of the trials, other istitutional investors will stay away. I believe, Rabin is counting on big pharmas' attraction after Phhase II ensues. Thus, a lot is likley to happen sometime later in 2013. My point is that this stock currently is not for traders, it's for investors seeking bottom fishing.